Reports Q3 revenue $138.96M, consensus $133.23M. “We delivered strong financial results in the third quarter, including double-digit organic growth and significantly increased cash flow,” said Rob Claypoole, Bioventus (BVS) President and Chief Executive Officer. “We remain focused on successfully executing on our strategic priorities to accelerate revenue growth, enhance profitability, and reduce our leverage to increase shareholder value.”
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BVS:
- Bioventus, Inc. (BVS) Q3 Earnings Cheat Sheet
- Bioventus files $200M mixed securities shelf
- Bioventus files to sell 35.04M shares of Class A common stock for holders
- Bioventus divesting advanced rehabilitation business to Accelmed Partners
- Bioventus price target raised to $17 from $12 at Craig-Hallum